AOP Health US LLC: RAPIBLYK® (landiolol) Approved by FDA for Use in Pediatric Patients with Supraventricular Tachycardia
AOP Health US, LLC today announced that the U.S. Food and Drug Administration (FDA) has approved RAPIBLYK® (landiolol) for use in pediatric patients (from birth to <18 years of age) with supraventricular tachycardia (SVT). This approval expands the availability of RAPIBLYK® beyond adults to patients of all ages in critical care settings and provides the first therapeutic option for pediatric patients with SVT in the US.
AOP Health US, LLC Awarded Pharmaceutical Agreement With Premier, Inc.
AOP Health US, LLC has been awarded a Pharmaceutical national group purchasing agreement with Premier, Inc. Effective August 1, 2025, the agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Rapiblyk® (landiolol).
AOP Health's Rapiblyk® (landiolol) Now Accessible via Vizient® Contract
AOP Health US, LLC announced today that Rapiblyk® (landiolol) is now more widely available across the United States through contract with Vizient®, the nation’s largest provider-driven healthcare performance improvement company. Hospitals and health systems nationwide now have increased access through the Vizient catalog to Rapiblyk®, enhancing flexibility while expanding the availability of this critical care therapy.
